JOHNSON & JOHNSON (JNJ)
WatchA data-driven read of JNJ's strengths and risk factors, built from its financials, earnings history, analyst activity, and insider trading, not opinion or speculation.
Five independent market signals, analysts, institutions, insiders, short sellers, and price trend, each scored from real, current data. See exactly where the smart money agrees, and where it's split.
Signals are mixed: 4 of 5 available lean bullish, 1 lean bearish.
Every trading day in the last 2 years where JNJ moved 4% or more in a single session, most recent first, a quick read on how volatile this stock has really been. See full daily price history →
| Date | Move | Close |
|---|---|---|
| Aug 19, 2026 | +4.21% | $273.41 |
| Jul 16, 2025 | +6.19% | $164.78 |
| Apr 4, 2025 | -4.12% | $153.24 |
| Apr 1, 2025 | -7.59% | $153.25 |
| Jan 27, 2025 | +4.13% | $152.89 |
Every major event from the past 12 months, earnings reports, insider transactions, and analyst upgrades or downgrades, merged into a single chronological feed so you can see what clustered together.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
One Johnson & Johnson Plaza, New Brunswick, NJ, 08933, United States, 732 524 0400
A complete statistical profile built from JNJ's full price, financial, and ownership history, not an isolated snapshot. Explore any category in depth below.
P/E uses trailing 12-month earnings where 4 recent quarters are on record, otherwise the latest fiscal year. PEG divides P/E by trailing revenue growth (a proxy, not true forward earnings growth, which this data doesn't include).